Claire’s Place Foundation Hosts 3rd Annual Glow Ride to Support Children with Cystic Fibrosis
August 30, 2017 09:00 ET
|
Claire's Place Foundation
Los Angeles, CA, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Claire’s Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis, is proud to announce...
ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial
August 29, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates Last patient received their final dose in the PQ-010-001 Phase 1b clinical trial of QR-010 in CF patients with the F508del mutation.Top-line trial data are expected to be issued in a...
ProQR Announces Results for the Second Quarter of 2017
August 16, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key updates Data from two clinical trials of QR-010 presented at the European Cystic Fibrosis Conference. Enrollment completed in the Phase 1b clinical trial in cystic fibrosis (CF) and top-line...
Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be Included in the European Cystic Fibrosis Clinical Trial Network
August 14, 2017 08:30 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that the RESULT Phase 3 clinical study of Sollpura for exocrine pancreatic insufficiency due...
Anthera Pharmaceuticals Provides Business Update and Reports 2017 Second Quarter Financial Results
August 09, 2017 08:30 ET
|
Anthera Pharmaceuticals, Inc.
RESULT, pivotal Phase 3 study of Sollpura began screening patients in the U.S. and EuropeRESULT study approved by the Cystic Fibrosis Foundation Therapeutics Development NetworkBRIGHT, Phase 2 study...
Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be included in the Cystic Fibrosis Foundation Therapeutics Development Network
July 10, 2017 08:30 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., July 10, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that the RESULT Phase 3 clinical study of Sollpura for exocrine pancreatic insufficiency due...
Anthera Announces Expansion of Screening in European Sites in Phase 3 RESULT Clinical Study of Sollpura
July 06, 2017 08:30 ET
|
Anthera Pharmaceuticals, Inc.
Study is being conducted in the US, Europe, and IsraelTop line data expected end of 2017 or early 2018 HAYWARD, Calif., July 06, 2017 (GLOBE NEWSWIRE) -- Anthera (Nasdaq:ANTH) today announced that...
ProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference
June 13, 2017 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, The Netherlands, June 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that Daniel de Boer, Chief Executive Officer, will participate in a panel discussion...
ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU
April 03, 2017 07:00 ET
|
ProQR Therapeutics
Key Updates ProQR received notice of grant for 2 key patents protecting QR-010 for CF in the US and EU until at least July 2033QR-010 is currently being studied in 64 homozygous F508del patients in a...
ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer
March 27, 2017 07:00 ET
|
ProQR Therapeutics
LEIDEN, the Netherlands, March 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it appointed David M. Rodman, MD as Chief Development Strategy Officer. Dr....